NextCure, Inc.
NXTC Healthcare Biotechnology
In the quarter to June 2026, EPS grew 75.2% and free cash flow grew 57.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow NXTC
NextCure, Inc. (NXTC) EV/Sales
As of 16 October 2026, NextCure, Inc. (NXTC) trades at a EV/Sales of 0.6×. Over the past ten years it has ranged from −4.9× (December 2022) to 92.1× (January 2020); the current reading is higher than 85% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2020 | 0.7× | (99.23%) |
| FY2019 | 87.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2020 | 25.6× | (70.61%) |
| Dec 2019 | 87.0× | — |
| Sep 2019 | 0.0× | — |
| Jun 2019 | 0.0× | — |
| 1 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MGX Metagenomi Therapeutics, Inc. compare | −4.5× |
| ATNM Actinium Pharmaceuticals, Inc. compare | 0.0× |
| RNAZ TransCode Therapeutics Inc. compare | n/m |
| BCTX BRIACELL THERAP compare | n/m |
| GRDX GridAI Technologies Corp. compare | n/m |
| GNTA Genenta Science S.p.A. Unsponsored ADR compare | n/m |
| NXTC NextCure, Inc. | 0.6× |
| ALGS Aligos Therapeutics, Inc. compare | 0.6× |
| CVM Cel-Sci Corporation compare | 35.0× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)